Detalhe da pesquisa
1.
Mirvetuximab Soravtansine in FRα-Positive, Platinum-Resistant Ovarian Cancer.
N Engl J Med
; 389(23): 2162-2174, 2023 Dec 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-38055253
2.
Molecular landscape of ERBB2/HER2 gene amplification among patients with gynecologic malignancies; clinical implications and future directions.
Gynecol Oncol
; 180: 1-5, 2024 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-38029652
3.
Phase 1b study of mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate, in combination with carboplatin and bevacizumab in patients with platinum-sensitive ovarian cancer.
Gynecol Oncol
; 185: 186-193, 2024 Mar 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-38447347
4.
Next generation sequencing reveals a high prevalence of pathogenic mutations in homologous recombination DNA damage repair genes among patients with uterine sarcoma.
Gynecol Oncol
; 177: 14-19, 2023 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-37611378
5.
NCCN Guidelines® Insights: Ovarian Cancer, Version 3.2022.
J Natl Compr Canc Netw
; 20(9): 972-980, 2022 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-36075393
6.
Evaluation of the management of PARP inhibitor toxicities in ovarian and endometrial cancer within a multi-institution health-system.
J Oncol Pharm Pract
; 28(5): 1102-1110, 2022 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-34134553
7.
Combination ATR and PARP Inhibitor (CAPRI): A phase 2 study of ceralasertib plus olaparib in patients with recurrent, platinum-resistant epithelial ovarian cancer.
Gynecol Oncol
; 163(2): 246-253, 2021 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-34620496
8.
Ovarian Cancer, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology.
J Natl Compr Canc Netw
; 19(2): 191-226, 2021 02 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-33545690
9.
Utilization and survival outcomes of sequential, concurrent and sandwich therapies for advanced stage endometrial cancers by histology.
Gynecol Oncol
; 159(2): 394-401, 2020 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-32800655
10.
Phase Ib study of mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients with platinum-resistant ovarian cancer.
Gynecol Oncol
; 157(2): 379-385, 2020 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-32081463
11.
Is Targeting the Folate Receptor in Ovarian Cancer Coming of Age?
Oncologist
; 24(4): 425-429, 2019 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-30635448
12.
Weekly vs. Every-3-Week Paclitaxel and Carboplatin for Ovarian Cancer.
N Engl J Med
; 374(8): 738-48, 2016 Feb 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-26933849
13.
Safety lead-in of the MEK inhibitor trametinib in combination with GSK2141795, an AKT inhibitor, in patients with recurrent endometrial cancer: An NRG Oncology/GOG study.
Gynecol Oncol
; 155(3): 420-428, 2019 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-31623857
14.
Safety and activity findings from a phase 1b escalation study of mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with carboplatin in patients with platinum-sensitive ovarian cancer.
Gynecol Oncol
; 151(1): 46-52, 2018 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-30093227
15.
Phase II evaluation of dalantercept in the treatment of persistent or recurrent epithelial ovarian cancer: An NRG Oncology/Gynecologic Oncology Group study.
Gynecol Oncol
; 150(3): 466-470, 2018 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-30041929
16.
Phase I combination study of the PARP inhibitor veliparib plus carboplatin and gemcitabine in patients with advanced ovarian cancer and other solid malignancies.
Gynecol Oncol
; 148(3): 507-514, 2018 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-29352572
17.
A review of mirvetuximab soravtansine in the treatment of platinum-resistant ovarian cancer.
Future Oncol
; 14(2): 123-136, 2018 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-29098867
18.
Characterization of folate receptor alpha (FRα) expression in archival tumor and biopsy samples from relapsed epithelial ovarian cancer patients: A phase I expansion study of the FRα-targeting antibody-drug conjugate mirvetuximab soravtansine.
Gynecol Oncol
; 147(2): 402-407, 2017 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-28843653
19.
Distress and Financial Distress in Adults With Cancer: An Age-Based Analysis.
J Natl Compr Canc Netw
; 15(10): 1224-1233, 2017 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-28982748
20.
Ovarian Cancer, Version 1.2016, NCCN Clinical Practice Guidelines in Oncology.
J Natl Compr Canc Netw
; 14(9): 1134-63, 2016 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-27587625